• Adefovir (GS-0393): Mechanistic Power and Translational Leve

  2026-05-13

  This thought-leadership article for translational researchers explores the mechanistic foundation, experimental best practices, and forward-looking strategic guidance for deploying Adefovir (GS-0393) in hepatitis B virus (HBV) research. Integrating current literature, competitive perspectives, and practical workflow insight, it positions Adefovir from APExBIO as a catalyst for reproducible and innovative HBV and transporter studies.

• Targeting FGFR2 Fusions in ICC with Heteroduplex Oligonucleo

  2026-05-13

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (Cho-HDO) that specifically suppresses FGFR2 fusion-driven intrahepatic cholangiocarcinoma (ICC) via LDLR-mediated uptake and posttranscriptional gene silencing. The work reveals a compensatory EGFR-STAT1-asparagine axis limiting efficacy, suggesting combined FGFR2 inhibition and asparagine depletion as a rational therapeutic strategy.

• TMRE Mitochondrial Membrane Potential Assay Kit: Evidence &

  2026-05-12

  The TMRE mitochondrial membrane potential assay kit enables sensitive, quantitative detection of mitochondrial health using a Tetramethylrhodamine ethyl ester mitochondrial probe. This kit, provided by APExBIO, is optimized for apoptosis research and mitochondrial function analysis, with validated controls and high-throughput applicability.

• GOB-38 Metallo-β-Lactamase in Elizabethkingia anophelis: Bio

  2026-05-12

  This study provides the first detailed biochemical and substrate specificity analysis of the novel GOB-38 metallo-β-lactamase in Elizabethkingia anophelis, revealing its broad-spectrum activity against β-lactam antibiotics. The findings highlight the potential clinical impact of GOB-38 and underscore the urgency of improved β-lactamase detection and resistance profiling in multidrug-resistant pathogens.

• Calcitriol in Decidualization and Immune Modulation Research

  2026-05-11

  Calcitriol (1,25-dihydroxy vitamin D3) unlocks precise control over endometrial decidualization and immune cytokine pathways, offering researchers targeted, reproducible experimental outcomes. This article translates new mechanistic findings into actionable workflows, troubleshooting, and protocol optimizations for advanced studies in reproductive and immune biology.

• Direct Mouse Genotyping Kit: Streamlined DNA from Mouse Tiss

  2026-05-11

  The Direct Mouse Genotyping Kit enables rapid extraction of PCR-ready genomic DNA directly from mouse tissue, eliminating the need for DNA purification. This solution is ideal for routine, high-throughput genotyping but should not be used where ultra-pure or high-molecular-weight DNA is required, such as for long-read sequencing or applications sensitive to minor PCR inhibitors.

• 2X Taq PCR Master Mix (with dye): Atomic Facts & Protocol Us

  2026-05-10

  The 2X Taq PCR Master Mix (with dye) is a ready-to-use PCR reagent from APExBIO, optimized for DNA amplification with integrated dye to streamline workflows. Its recombinant Taq DNA polymerase supports efficient genotyping, cloning, and sequence analysis, providing reliable adenine overhangs for TA cloning.

• Netrin-1 Impairs Adipogenesis via PPARγ and Wnt/β-catenin Pa

  2026-05-09

  This study uncovers a direct inhibitory role for adipose-derived Netrin-1 in adipogenesis, mediated through suppression of PPARγ and activation of Wnt/β-catenin signaling. These findings highlight Netrin-1 as a potential therapeutic target in high-fat-diet-induced obesity and type 2 diabetes by modulating adipose tissue remodeling and metabolic health.

• Birinapant (TL32711): Optimized Workflows for Apoptosis Indu

  2026-05-08

  Birinapant (TL32711) is redefining apoptosis research through high-affinity IAP antagonism, enabling precise modulation of cell death pathways in cancer models. This guide details experimental workflows, troubleshooting, and the translational impact of integrating Birinapant into chemoradiotherapy sensitivity studies. APExBIO's formulation ensures reliability for both in vitro and in vivo applications.

• Light-Inducible RNA Switches for Precision Gene Therapies

  2026-05-08

  This study presents a rationally engineered, light-inducible RNA-releasing protein (LIRP) that enables reversible, spatiotemporal control of therapeutic gene expression in vivo. The findings establish a practical translational gene regulation platform, with demonstrated advantages for chronic metabolic and retinal disease models.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI: CDCA Mechani

  2026-05-07

  This study uncovers how Chenodeoxycholic Acid (CDCA) activates the FXR-KLF11 pathway to mitigate contrast-induced acute kidney injury (CI-AKI) by suppressing JAK2/STAT3 signaling. These insights advance mechanistic understanding of FXR agonists in renal protection and inform future research in bile acid metabolism and nuclear receptor signaling.

• Cycloheximide: Protein Biosynthesis Inhibitor for Translatio

  2026-05-07

  Cycloheximide from APExBIO offers precise, rapid, and reversible inhibition of protein synthesis, enabling high-resolution analysis of apoptosis, protein turnover, and posttranslational regulation. Its validated workflows and high purity empower researchers to dissect complex cellular pathways with unmatched specificity.

• Palonosetron in CINV Prevention: Efficacy and Mechanistic In

  2026-05-06

  Ruhlmann and Herrstedt's review rigorously evaluates palonosetron hydrochloride, a next-generation 5-HT3 antagonist, for preventing chemotherapy-induced nausea and vomiting (CINV). The paper details pharmacologic distinctions, clinical trial outcomes, and comparative efficacy, providing an evidence-driven framework for optimizing antiemetic protocols in oncology research and practice.

• DRB in Translational Research: Beyond Transcriptional Inhibi

  2026-05-06

  Explore how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is revolutionizing translational research by precisely modulating transcriptional elongation and cyclin-dependent kinase signaling. This article offers mechanistic insights, strategic guidance for experimental design, and an outlook on DRB’s evolving role in cell fate, antiviral, and epitranscriptomic research.

• MDM1 Overexpression Enhances Chemoradiotherapy Sensitivity i

  2026-05-05

  This study demonstrates that MDM1 overexpression in colorectal cancer cells increases p53 expression and apoptosis, thereby enhancing sensitivity to chemoradiotherapy. The findings establish MDM1 as a promising predictive biomarker and provide mechanistic insight into overcoming treatment resistance in CRC.

15635 records 1/1043 page Next 12345 下5页 Last page